Overview

Study to Evaluate the Efficacy and Safety of APL-2 in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)

Status:
Completed
Trial end date:
2020-08-13
Target enrollment:
Participant gender:
Summary
Evaluation of the Efficacy and Safety of APL-2 in Patients with Paroxysmal Nocturnal Hemoglobinuria
Phase:
Phase 3
Details
Lead Sponsor:
Apellis Pharmaceuticals, Inc.
Treatments:
Complement System Proteins
Eculizumab